Researchers have explored the potential of glucagon-like peptide-1 (GLP-1) receptor agonists in treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s. A recent study by Paul Edison, MD, PhD, at Imperial College London found that GLP-1 analogs reduced neuroinflammation and tau tangle deposits in animal models of Alzheimer’s disease.
Studies have shown promising results with GLP-1 receptor agonists in treating cognitive impairment and dementia, including a lower risk of Alzheimer’s disease. However, the effectiveness of these drugs varies depending on their blood-brain barrier penetrability. Edison noted that some studies have positive results while others are negative, and it may be due to differences in drug penetration.
Despite this, GLP-1 receptor agonists have shown promise in reducing inflammation, oxidative stress, and neuronal damage. Next-generation drugs with triple agonism may have even more potent neuroprotective effects. However, Edison emphasized that the field is still debating the effectiveness of these drugs and needs further research to fully understand their potential.
The results of ongoing phase III trials, such as EVOKE and EVOKE Plus, will provide crucial insights into the disease-modifying potential of semaglutide in people with early-stage symptomatic Alzheimer’s disease. These trials aim to assess the effects of semaglutide on Alzheimer’s biomarkers and neuroinflammation.
Source: https://www.medpagetoday.com/meetingcoverage/aan/114996